Enjoy complimentary customisation on priority with our Enterprise License!
The polycystic ovary syndrome (PCOS) drugs market share is expected to increase by USD 711.14 million from 2020 to 2025, and the market’s growth momentum will accelerate at a CAGR of 5%.
The market research report provides valuable insights into the post-COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers market segmentation by drug class (insulin-sensitizing agents, oral contraceptives, aromatase inhibitors, and other drug classes) and geography (North America, Europe, Asia, and ROW).
The polycystic ovary syndrome (PCOS) drugs market report also offers information on several market vendors, including AbbVie Inc., Bayer AG, Bristol-Myers Squibb Co., Cipla Inc., Ferring Pharmaceuticals AS, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. among others.
AbbVie Inc. - VANIQA: It is used to slow down the growth of unwanted hair on the face and under the chin in women with PCOS. Under the unified segment, the company operates in only one business segment that focuses on the discovery, development, manufacturing, and commercialization of drugs for the treatment of various indications.
Get the Polycystic Ovary Syndrome (PCOS) Drugs Market Size Forecast by Downloading the Report Sample
Technavio categorizes the global PCOS drugs market as a part of the pharmaceutical market within the overall healthcare industry. Our research report extensively covers external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the polycystic ovary syndrome (PCOS) drugs market during the forecast period.
Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Key Polycystic Ovary Syndrome (PCOS) Drugs Market Driver
Key Polycystic Ovary Syndrome (PCOS) Drugs Market Challenge
This polycystic ovary syndrome (PCOS) drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
Our In-house experts produce extensive information on the value chain and parent market of the polycystic ovary syndrome (PCOS) drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The Value Chain information provides an end-to-end understanding of product insight and profit and also optimization and evaluation of business strategies. The players across the value chain include selective data and analysis from entire research findings as per the scope of the report.
Get a glance at the market share of various regions by Requesting a PDF Sample now!
35% of the market’s growth will originate from North America during the forecast period. The US is the key market for polycystic ovary syndrome (PCOS) drugs in North America. Market growth in this region will be faster than the growth of the market in the European regions.
The presence of well-established pharmaceutical giants in the region and huge investments from governments for patient assistance and R&D activities will result in the region accounting for a high share of the global PCOS drugs market during the forecast period. This will facilitate the polycystic ovary syndrome (PCOS) drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
To gain insights on the market contribution of various segments Request a PDF Sample
The polycystic ovary syndrome (PCOS) drugs market share growth by the insulin sensitizing agents segment will be significant during the forecast period. Insulin-sensitizing agents such as metformin are used for women with PCOS, oligo/amenorrhea, and subfertility since the administration of these agents improves the chances of clinical pregnancy and ovulation. Thus, the benefits of insulin-sensitizing agents in PCOS patients are expected to drive the sales of PCOS drugs during the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the polycystic ovary syndrome (PCOS) drugs market size and actionable market insights on the post-COVID-19 impact on each segment.
Polycystic Ovary Syndrome (PCOS) Drugs Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2020 |
Forecast period |
2021-2025 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5% |
Market growth 2021-2025 |
$ 711.14 million |
Market structure |
Fragmented |
YoY growth (%) |
4.41 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
North America at 35% |
Key countries |
US, Germany, UK, Japan, and France |
Competitive landscape |
Leading companies, Competitive Strategies, Consumer engagement scope |
Key companies profiled |
AbbVie Inc., Bayer AG, Bristol-Myers Squibb Co., Cipla Inc., Ferring Pharmaceuticals AS, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by Drug Class
Customer landscape
Geographic Landscape
Vendor Landscape
Vendor Analysis
Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.